All
Genomics Data Could Lead to New Treatments for Children
March 12th 2019St. Jude Children’s Research Hospital is offering cloud-based access to the fully sequenced genomes of 10,000 pediatric patients with cancer, in the hopes that sharing the information will lead to the highest possible number of treatment breakthroughs.
The Devil We Know: Secondhand Smoke and Cancer Fears
March 12th 2019As a breast cancer survivor, I have become more active in my efforts to call attention to problems with secondhand smoke in my community. Since I know that exposure is not healthy, lobbying for changes in attitudes, as well as policies, makes me feel more empowered.
The FDA Approves Fourth Herceptin Biosimilar
March 12th 2019The Food and Drug Administration (FDA) has granted an approval to Trazimera (PF-05280014; trastuzumab-qyyp), a Herceptin (trastuzumab) biosimilar, to treat patients with HER2-overexpressing breast cancer as well as HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.
FDA Approves Assay to Determine Eligibility for Tecentriq in Triple-Negative Breast Cancer
March 11th 2019The Food and Drug Administration approved the VENTANA PD-L1 (SP142) Assay as the first companion diagnostic to aid in identifying patients with triple-negative breast cancer who are eligible for treatment with Tecentriq (atezolizumab) plus chemotherapy.
Dealing with Shoulder Pain After Breast Cancer Treatment
March 9th 2019Breast cancer treatment is a life-saver but also can have side effects, including some related to shoulder pain. It is good to start doing the exercises as soon as the doctor recommends it. After that, a regular tune-up with a physical therapist can help.
FDA Approves Tecentriq Combo for Frontline TNBC
March 8th 2019The Food and Drug Administration has granted an accelerated approval to the frontline combination of Tecentriq (atezolizumab) plus Abraxane (nab-paclitaxel) for patients with unresectable locally advanced or metastatic PD-L1–positive triple-negative breast cancer (TNBC).